Showing results (91-100 of 143) with videos related to

Sort By:
Pageof 15
Cell Reports|June 20, 2019
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor SensitivityLynnette Marcar, Kankana Bardhan, Liliana Gheorghiu, et al.
JTO Clinical and Research Reports|September 19, 2022
Clinicopathologic Characteristics and Outcomes for Patients With KRAS G12D-Mutant NSCLCAlissa J Cooper, Alona Muzikansky, Jochen Lennerz, et al.
Clinical Lung Cancer|December 10, 2021
Chemotherapy Plus Immunotherapy Versus Chemotherapy Plus Bevacizumab Versus Chemotherapy Alone in EGFR-Mutant NSCLC After Progression on OsimertinibMaya N White, Andrew J Piper-Vallillo, Rebecca M Gardner, et al.
JTO Clinical and Research Reports|July 11, 2022
A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on CrizotinibJaime L Schneider, Alona Muzikansky, Jessica J Lin, et al.
Clinical Lung Cancer|March 24, 2020
Expanding Access to Lung Cancer Clinical Trials by Reducing the Use of Restrictive Exclusion Criteria: Perspectives of a Multistakeholder Working GroupPatrick M Forde, Phil Bonomi, Alice Shaw, et al.
JCO Precision Oncology|June 4, 2025
ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line OsimertinibJonathan W Riess, Adrianus J de Langen, Santiago Ponce, et al.
JCO Precision Oncology|June 21, 2021
Randomized Phase II Study of 3 Months or 2 Years of Adjuvant Afatinib in Patients With Surgically Resected Stage I-III EGFR-Mutant Non-Small-Cell Lung CancerJoel W Neal, Daniel B Costa, Alona Muzikansky, et al.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Prevalence and Actionability of MTAP Loss in Oncogene-Driven Lung CancerTakashi Sakai, Zofia Piotrowska, Charlotte I Wang, et al.
The Oncologist|June 2, 2019
Safety and Success of Repeat Lung Needle Biopsies in Patients with Epidermal Growth Factor Receptor-Mutant Lung CancerFlorian J Fintelmann, Fabian M Troschel, Martin W Kuklinski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 6, 2026
Genomic Profiling of Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Post-Progression on First-Line Osimertinib: Phase II ORCHARD StudyHelena A Yu, Kwan Ho Tang, Aleksandra A Markovets, et al.
Pageof 15